Compare Stocks: REPL, ACAD, EWTX, and PBLS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$27.83 +0.3%	$27.52	$19.69 ▼ $30.96	$4.78B	0.86	1.32 million shs	1.17 million shs
EWTX Edgewise Therapeutics	$44.40 +3.5%	$42.56	$13.69 ▼ $48.40	$4.66B	0.32	1.02 million shs	1.40 million shs
PBLS Parabilis Medicines	$36.88 +1.5%	$35.13	$24.51 ▼ $41.49	$4.49B	N/A	401,417 shs	364,813 shs
REPL Replimune Group	$12.92 -2.4%	$12.53	$1.50 ▼ $16.33	$1.24B	0.94	2.23 million shs	4.09 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.32%	-0.68%	-5.50%	+31.96%	+16.93%
EWTX Edgewise Therapeutics	+3.50%	+3.09%	+1.93%	+27.48%	+202.66%
PBLS Parabilis Medicines	+1.54%	-8.76%	-1.42%	+35.29%	+3,687,999,900.00%
REPL Replimune Group	-2.42%	-14.10%	-15.22%	+45.50%	+115.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$27.83 +0.3%	$27.52	$19.69 ▼ $30.96	$4.78B	0.86	1.32 million shs	1.17 million shs
EWTX Edgewise Therapeutics	$44.40 +3.5%	$42.56	$13.69 ▼ $48.40	$4.66B	0.32	1.02 million shs	1.40 million shs
PBLS Parabilis Medicines	$36.88 +1.5%	$35.13	$24.51 ▼ $41.49	$4.49B	N/A	401,417 shs	364,813 shs
REPL Replimune Group	$12.92 -2.4%	$12.53	$1.50 ▼ $16.33	$1.24B	0.94	2.23 million shs	4.09 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.32%	-0.68%	-5.50%	+31.96%	+16.93%
EWTX Edgewise Therapeutics	+3.50%	+3.09%	+1.93%	+27.48%	+202.66%
PBLS Parabilis Medicines	+1.54%	-8.76%	-1.42%	+35.29%	+3,687,999,900.00%
REPL Replimune Group	-2.42%	-14.10%	-15.22%	+45.50%	+115.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.78	Moderate Buy	$34.36	23.47% Upside
EWTX Edgewise Therapeutics	2.82	Moderate Buy	$50.33	13.36% Upside
PBLS Parabilis Medicines	2.71	Moderate Buy	$41.67	12.98% Upside
REPL Replimune Group	2.60	Moderate Buy	$12.00	-7.12% Downside

Current Analyst Ratings Breakdown

Latest REPL, ACAD, EWTX, and PBLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	PBLS Parabilis Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
8/26/2026	REPL Replimune Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$20.00 ➝ $21.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$27.00 ➝ $28.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/20/2026	EWTX Edgewise Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$53.00 ➝ $60.00
8/17/2026	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $49.00
8/12/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/12/2026	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/12/2026	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $41.00
8/11/2026	REPL Replimune Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	4.48	$0.89 per share	31.27	$7.25 per share	3.84
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.93 per share	N/A
PBLS Parabilis Medicines	$148K	30,783.09	N/A	N/A	N/A	∞
REPL Replimune Group	N/A	N/A	N/A	N/A	$2.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	12.54	28.40	N/A	33.42%	9.03%	6.79%	11/4/2026 (Estimated)
EWTX Edgewise Therapeutics	-$167.79M	-$1.85	N/A	N/A	N/A	N/A	-39.01%	-36.96%	11/5/2026 (Estimated)
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	-$313.94M	-$3.15	N/A	N/A	N/A	N/A	-159.32%	-90.84%	11/5/2026 (Estimated)

Latest REPL, ACAD, EWTX, and PBLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q1 2027	REPL Replimune Group	-$0.6940	-$0.72	-$0.0260	-$0.72	$13.60 million	N/A
8/13/2026	Q2 2026	PBLS Parabilis Medicines	-$0.16	-$2.32	-$2.16	-$2.32	N/A	$0.15 million
8/6/2026	Q2 2026	EWTX Edgewise Therapeutics	-$0.4677	-$0.53	-$0.0623	-$0.53	N/A	N/A
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million
6/29/2026	Q4 2026	REPL Replimune Group	-$0.6613	-$0.76	-$0.0988	-$0.76	$3.57 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.30
EWTX Edgewise Therapeutics	N/A	16.24	16.24
PBLS Parabilis Medicines	N/A	N/A	N/A
REPL Replimune Group	1.00	5.23	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
EWTX Edgewise Therapeutics	N/A
PBLS Parabilis Medicines	N/A
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
EWTX Edgewise Therapeutics	21.30%
PBLS Parabilis Medicines	N/A
REPL Replimune Group	5.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	798	172.31 million	127.16 million	Optionable
EWTX Edgewise Therapeutics	127	108.60 million	85.47 million	Optionable
PBLS Parabilis Medicines	145	123.53 million	N/A	N/A
REPL Replimune Group	210	93.80 million	88.73 million	Optionable

REPL, ACAD, EWTX, and PBLS Headlines

Recent News About These Companies

Short Interest Falls Across Five Stocks

September 12 at 5:54 AM | ijr.comI

REPL Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against Replimune Group, Inc.

September 11 at 5:48 PM | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

September 11 at 1:00 PM | newsfilecorp.comN

Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Replimune Group Inc. and Encourages Investors to Contact the Firm

September 11 at 12:38 PM | globenewswire.com

REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact Levi & Korsinsky

September 11 at 10:11 AM | businesswire.com

Opaleye Management Inc. Buys Shares of 1,384,993 Replimune Group, Inc. $REPL

September 11 at 5:28 AM | marketbeat.com

Replimune Group (NASDAQ:REPL) Shares Down 6.9% - Here's Why

September 10 at 1:59 PM | marketbeat.com

REPL Investor Alert: Replimune Group, Inc. Securities Class Action Notice - Contact SueWallSt

September 10 at 10:09 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

September 10 at 10:00 AM | prnewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

September 9 at 1:00 PM | newsfilecorp.comN

REPL Deadline Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026

September 9 at 10:07 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

September 8, 2026 | globenewswire.com

REPL UPCOMING DEADLINE: SueWallSt Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm

September 8, 2026 | globenewswire.com

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

September 8, 2026 | globenewswire.com

Bank of New York Mellon Corp Takes $2.61 Million Position in Replimune Group, Inc. $REPL

September 8, 2026 | marketbeat.com

Readystate Asset Management LP Purchases 161,470 Shares of Replimune Group, Inc. $REPL

September 7, 2026 | marketbeat.com

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

September 4, 2026 | globenewswire.com

Replimune Group (NASDAQ:REPL) Sets New 1-Year High - Here's Why

September 4, 2026 | americanbankingnews.com

Replimune Group (NASDAQ:REPL) Stock Price Down 5.3% - Should You Sell?

September 3, 2026 | marketbeat.com

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

September 3, 2026 | globenewswire.com

Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

September 3, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL, ACAD, EWTX, and PBLS Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$27.83 +0.09 (+0.32%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$28.08 +0.25 (+0.88%)

As of 09/11/2026 07:34 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Edgewise Therapeutics NASDAQ:EWTX

$44.40 +1.50 (+3.50%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$43.90 -0.50 (-1.14%)

As of 09/11/2026 07:30 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Parabilis Medicines NASDAQ:PBLS

$36.88 +0.56 (+1.54%)

As of 09/11/2026 04:00 PM Eastern

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.

Replimune Group NASDAQ:REPL

$12.92 -0.32 (-2.42%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$12.82 -0.10 (-0.74%)

As of 09/11/2026 07:30 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REPL, ACAD, EWTX, and PBLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REPL, ACAD, EWTX, and PBLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REPL, ACAD, EWTX, and PBLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL, ACAD, EWTX, and PBLS Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Edgewise Therapeutics NASDAQ:EWTX

Parabilis Medicines NASDAQ:PBLS

Replimune Group NASDAQ:REPL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REPL, ACAD, EWTX, and PBLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REPL, ACAD, EWTX, and PBLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REPL, ACAD, EWTX, and PBLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL, ACAD, EWTX, and PBLS Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Edgewise Therapeutics NASDAQ:EWTX

Parabilis Medicines NASDAQ:PBLS

Replimune Group NASDAQ:REPL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools